The prices of drugs used to treat COVID-19 for those at risk of serious illness are “reasonably aligned” with how much they help patients, according to a draft report from drug-pricing research organisation the Institute for Clinical and Economic Review (ICER). The report assessed Pfizer Inc’s Paxlovid and Merck & Co’s molnupiravir – both recently […]